AGM/EGMApr 28, 2026, 06:13 AM
ONC 2026 Annual General Meeting on June 11; 2025 GAAP Profitability
AI Summary
BeOne Medicines Ltd. (ONC) filed its definitive proxy statement for its 2026 Annual General Meeting of Shareholders to be held on June 11, 2026. The company reported a remarkable 2025, achieving GAAP profitability for the first time and generating meaningful cash flow, driven by strong topline revenue growth, including BRUKINSA's $3.9 billion in global revenues. Key proposals for the AGM include the approval of 2025 financial statements, election of directors, and mandates for share issuance and repurchase.
Key Highlights
- ONC 2026 Annual General Meeting scheduled for June 11, 2026.
- Achieved GAAP profitability and meaningful cash flow for the first time in 2025.
- BRUKINSA global revenues reached $3.9 billion in 2025, a 49% increase.
- Over 2 million patients treated with company medicines globally.
- Sonrotoclax received its first global regulatory approval in late 2025.
- Proposed share issue mandate up to 20% of total issued shares.
- Proposed share repurchase mandate up to 10% of total issued shares.